论文部分内容阅读
喹噁哌嗪(doxazosin)是一种高度选择性α_1肾上腺素能受体拮抗剂。晚近,动物实验及临床研究已证实其抗高血压作用。本文通过25例肾性高血压或合并肾功能不全高血压病人的观察和治疗试验,旨在评价喹(口恶)派嗪的疗效、安全性及总临床效果。方法:选择慢性肾小球肾炎、慢性肾盂肾炎高血压或合并肾功能不全高血压的住院病人10例及门诊病人15例分两组人为研究对象,男11例,女14 例,年龄25～70岁,其收缩压(SBP)≥160mmHg或舒张压(DBP)≥mmHg,或血压≥150/90mmHg,血肌酐132.5～442.0μmol/L。试验分观察期和治疗期。观察期住院组≥1周,门诊组≥4周,每日晨服一次安慰剂或伴服利尿剂;治疗期住院组4周,门诊
Doxazosin is a highly selective alpha 1 adrenergic receptor antagonist. Recently, animal experiments and clinical studies have confirmed its antihypertensive effect. This article through 25 cases of renal hypertension or renal insufficiency patients with hypertension observation and treatment trials to evaluate the curative effect, safety and overall clinical effect of quinoxaline. Methods: There were 10 inpatients with chronic glomerulonephritis, chronic pyelonephritis or hypertension with renal insufficiency and 15 outpatients in two groups, including 11 males and 14 females, aged 25-70 years old Year old with systolic blood pressure (SBP) ≥160mmHg or diastolic blood pressure (DBP) ≥mmHg or blood pressure ≥150 / 90mmHg and serum creatinine 132.5 ~ 442.0μmol / L. Test points observation period and treatment period. During the observation period, the hospitalized group was ≥1 weeks, the outpatient group was ≥4 weeks, the morning daily was given a placebo or concomitant diuretic; the hospitalization period was 4 weeks, and the outpatient department